Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 9/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060473 | 0.87 | CA2 (0.48) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL10765775 | 0.84 | KMT2A (0.49) | KMT2AMEN1NLRP3ACHEALDH1A1 | |
| SCHEMBL13656915 | 0.82 | KMT2A (0.50) | KMT2AMEN1NLRP3ACHEALDH1A1 | |
| SCHEMBL751112 | 0.82 | KMT2A (0.50) | KMT2AMEN1NLRP3ACHEALDH1A1 | |
| SCHEMBL9733973 | 0.82 | KMT2A (0.50) | KMT2AMEN1NLRP3ACHEALDH1A1 | |
| SCHEMBL18402627 | 0.80 | KMT2A (0.49) | KMT2AMEN1NLRP3ACHEALDH1A1 | |
| SCHEMBL11965108 | 0.79 | LOXL2 (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL26489351 | 0.79 | KMT2A (0.47) | KMT2AMEN1ACHEALDH1A1MAPT | |
| SCHEMBL25767012 | 0.78 | ACHE (0.48) | KMT2AMEN1NLRP3ACHEALDH1A1 | |
| SCHEMBL10764574 | 0.78 | KMT2A (0.44) | KMT2AMEN1NLRP3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11912736-B2 | Diaryl trehalose compounds and uses thereof | THE UNIVERSITY OF MONTANA (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2022-06-30 | — | — | US | disclosed |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190016723-A9 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-07-12 | — | — | US | disclosed |
| US-8367712-B2 | Substituted amide beta secretase inhibitors | Merck, Sharp & Dohme, Corp. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8012953-B2 | Macrocyclic beta-secretase inhibitors | SCHERING CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-7652003-B2 | Macrocyclic β-secretase inhibitors | SCHERING-PLOUGH CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-7101892-B2 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. | 2006-09-05 | — | — | US | disclosed |
| WO-2006014944-A1 | MACROCYCLIC BETA-SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | HTR7, HTR2C, HTR1A | KMT2A 2168/4885MEN1 4149/4885NLRP3 3226/4885 |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | KMT2A 2078/4885MEN1 2566/4885NLRP3 594/4885 |
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | KMT2A 4225/4885MEN1 3633/4885NLRP3 1627/4885 |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | KMT2A 4141/4885MEN1 3889/4885NLRP3 1688/4885 |
| US-20220204497-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | TPX2, AIMP2, CDYL2 | KMT2A 1721/4885MEN1 479/4885NLRP3 263/4885 |
| US-20190016723-A9 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | KMT2A 4309/4885MEN1 3885/4885NLRP3 1660/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | KMT2A 1449/4885MEN1 3032/4885NLRP3 2486/4885 |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | IDE, SI, GPR119 | KMT2A 4309/4885MEN1 3885/4885NLRP3 1660/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | KMT2A 3983/4885MEN1 3781/4885NLRP3 2074/4885 |
| US-11912736-B2 | Diaryl trehalose compounds and uses thereof | TREH, STT3B, DDOST | KMT2A 4228/4885MEN1 3708/4885NLRP3 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.